Gary Douglas Hammer MD

Professor, Internal Medicine
Endocrinology, Internal Medicine
Clinical Interests:
Adrenal cancer, adrenal masses, and adrenal disease

Video profile


U of M Internal Medicine Metabolism Endocrinology & Diabetes

Cancer Center Floor B1, Reception B
1500 E Medical Center Dr SPC 5354
Ann Arbor


Medical School or Training

  • Tufts University School of Medicine, 1992


  • University of California, San Francisco, Internal Medicine, CA, 1994


  • Endocrinology & Metabolism, University of California, San Francisco, 1997

Board Certification

  • Endocrinology, Diabetes & Metabolism


Molecular biology of adrenal growth disorders - hypoplasia, hyperplasia, adenomas and cancer.


Gary D. Hammer, M.D., Ph.D. serves as the director of the Endocrine Oncology Program in the Comprehensive Cancer Center, where he holds the Millie Schembechler Professorship in Adrenal Cancer. Under his leadership, the program was selected as one of five inaugural Destination Programs singled out for research and clinical excellence at UMHS. The program is uniquely recognized as an international center of excellence for the treatment of adrenal cancer.

Dr. Hammer is also director of the University Center for Organogenesis, which brings together groups and faculty's basic scientists and clinician's focused on organ-specific problems spanning developmental disorders to cancer. Strong relationships with the stem cell community, tissue and biomedical engineering, and clinical programs provide unparalleled opportunity for translational partnerships.

Research projects in Dr. Hammer's laboratory are aimed at elucidating the mechanisms by which growth factor signaling and transcriptional programs initiate adrenal-specific growth and differentiation with an emphasis on dysregulated growth of adrenocortical stem/progenitor cells in development and cancer. This work has led to the development of new national and international therapeutic trials with biological-based therapies for adrenal cancer that target the molecular defects in cancer stem cells while sparing normal tissue.